A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis

NCT04541810 · clinicaltrials.gov ↗

COMPLETED

Status

2369

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis (RA)
Atopic Dermatitis (AD)
Ankylosing Spondylitis (AS)
Psoriatic Arthritis (PsA)

Sponsor

AbbVie